Johnson & Johnson (JNJ:NYE) On Track to Exceed Earnings Expectations Once More

JNJ Stock Forecast

On April 18, Johnson & Johnson (JNJ:NYE) will release its first-quarter earnings report, with analysts anticipating revenues of $23.62 billion, a modest increase over the prior-year period. Despite significant headwinds in the first quarter, J&J has a history of consistently exceeding earnings projections. As a result of inflationary cost headwinds, inventory issues, and pricing pressure, Wall Street expects JNJ to report earnings per share of $2.51, down from $2.67 in the prior-year quarter.

JNJ’s first-half financial results may be impacted by sustained declines in Loss of Exclusivity (LOE) products in Europe and pricing pressure in the Pharmaceuticals division, but Wells Fargo analyst Larry Biegelsen anticipates that the company will “at least” meet consensus estimates.

The company expects new product introductions to drive a stronger second half of 2023, with projected adjusted operational sales growth of 4% (excluding the COVID-19 vaccine) and adjusted operational EPS growth of 3.5% to $10.50 per share.

 

JNJ Stock Forecast:

Despite near-term obstacles, J&J’s Pharmaceutical and MedTech portfolio is well-positioned to generate strong financial results. JNJ stock forecast shows an average price target of $177.76 which indicates an upside potential of 7.94%, with four Buy recommendations and ten Hold recommendations for a consensus rating of Buy.

JNJ Ratings by Stock Target Advisor

Company Profile:

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide.

The company’s Pharmaceutical segment provides products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes, and macular degeneration; and pulmonary arterial hypertension.

Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Top Trending Stocks

AVG Analyst Rating STA Analysis
StockTargetAdvisor
Buy
StockTargetAdvisor
Slightly Bullish
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Slightly Bullish
StockTargetAdvisor
Buy
StockTargetAdvisor
Slightly Bullish
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Slightly Bullish
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Slightly Bullish
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Slightly Bullish
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Bullish
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Slightly Bullish
StockTargetAdvisor
Buy
StockTargetAdvisor
Very Bullish
StockTargetAdvisor
Buy
StockTargetAdvisor
Slightly Bullish
Ad
Ad

Leave a Reply

Your email address will not be published. Required fields are marked *